A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer

被引：0
|
作者：
Mackay, H
Major, P
Townsley, C
Mackenzie, M
Vincent, M
Degendorfer, P
Tsao, M
Hedley, D
Wright, J
Oza, A
机构：
[1] Princess Margaret Phase II Consortium, Toronto, ON, Canada
[2] NCI, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3109
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [21] PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
    Alberts, SR
    Foster, NR
    Morton, RF
    Kugler, J
    Schaefer, P
    Wiesenfeld, M
    Fitch, TR
    Steen, P
    Kim, GP
    Gill, S
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1654 - 1661
  • [22] Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
    Adams, J
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) : 493 - 500
  • [23] PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) randomized phase II study
    Alberts, Steven R.
    Gill, Sharlene
    Foster, Nathan
    Morton, Roscoe
    Kugier, John
    Schaefer, Paul
    Sargent, Daniel
    ANNALS OF ONCOLOGY, 2004, 15 : 240 - 241
  • [24] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [25] The effect of the proteosome inhibitor, PS 341 on leiomyosarcoma cells.
    D'Amato, GZ
    Windham, TC
    Keschman, EA
    Mohapatra, S
    Burns, AC
    Muro-Cacho, BC
    Jove, R
    Sullivan, D
    Letson, GD
    Pledger, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 826S - 826S
  • [26] Current clinical trials for the proteasome inhibitor PS-341
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (11): : 1589 - +
  • [27] Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors
    Messersmith, WA
    Baker, SD
    Dinh, K
    Lassiter, LK
    Akdamar, RA
    Wright, JJ
    Donehower, RC
    Carducci, MA
    Armstrong, DK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 208S - 208S
  • [28] Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Mack, PC
    Davies, AM
    Lara, PN
    Gumerlock, PH
    Gandara, DR
    LUNG CANCER, 2003, 41 : S89 - S96
  • [29] Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group
    Gilbert, Jill
    Lee, Ju Whei
    Argiris, Athanassios
    Haigentz, Missak, Jr.
    Feldman, Lawrence Eric
    Jang, Minyoung
    Arun, Pattatheyil
    Van Waes, Carter
    Forastiere, Arlene A.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2013, 35 (07): : 942 - 948
  • [30] Proteasome inhibition in cancer: Development of PS-341
    Adams, J
    SEMINARS IN ONCOLOGY, 2001, 28 (06) : 613 - 619
12345